Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aridis Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ARDS
Over the counter
8731
https://aridispharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
- Dec 15th, 2023 9:15 pm
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
- Nov 3rd, 2023 8:15 pm
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
- Sep 22nd, 2023 5:30 pm
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
- Sep 15th, 2023 1:00 pm
Aridis Pharmaceuticals Announces $2 Million Offering
- Aug 2nd, 2023 12:17 pm
Why Are Aridis Pharmaceuticals Shares Moving Higher Today?
- Jul 18th, 2023 3:09 pm
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
- Jul 17th, 2023 8:05 pm
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
- Jul 13th, 2023 2:48 pm
Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
- Jul 12th, 2023 12:00 pm
Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
- Jun 30th, 2023 1:00 pm
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
- Jun 21st, 2023 2:59 pm
Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)
- Jun 20th, 2023 12:00 pm
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update
- Jun 8th, 2023 8:05 pm
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
- Jun 1st, 2023 3:24 pm
Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design
- May 31st, 2023 12:00 pm
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q
- May 25th, 2023 8:05 pm
Scroll